Angiotensin, fibrinolysis, and vascular homeostasis

American Journal of Cardiology

Volumn 87, Issue 8 SUPPL., 2001, Pages 18-24

  Vaughan, Douglas E ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; NITRIC OXIDE;

ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; ENDOTHELIUM LESION; FIBRINOLYSIS; HOMEOSTASIS; HUMAN; ISCHEMIC HEART DISEASE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; VASCULAR ENDOTHELIUM;

EID: 0035912117     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(01)01509-0     Document Type: Article

References (60)

1. Role of the fibrinolytic system in preventing myocardial infarction
2. Plasminogen activator inhibitors: A review
3. Kinetics of the activation of plasminogen by human tissue plasminogen activator: Role of fibrin
4. Interaction of one-chain and two-chain tissue plasminogen activator with intact and plasmin-degraded fibrin
5. Differences between binding of one-chain and two-chain tissue plasminogen activators to non-cross-linked and cross-linked fibrin clots
6. Plasminogen activator inhibitors
7. The mechanism of the reaction between human plasminogen-activator inhibitor 1 and tissue plasminogen activator
8. Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA): Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA
9. Angiotensin II increases plasminogen activator inhibitor type 1 and tissue-type plasminogen activator messenger RNA in cultured rat aortic smooth muscle cells
10. Studies on the acute release of tissue-type plasminogen activator from human endothelial cells in vitro and in rats in vivo: Evidence for a dynamic storage pool
11. Thrombin induction of plasminogen activator-inhibitor in cultured human endothelial cells
12. Vascular-bed-specific hemostasis and hypercoagulable states
13. A targeted point mutation in thrombomodulin generates viable mice with a prethrombotic state
14. The role of plasminogen activation in smooth muscle cell migration after arterial injury
15. Prothrombotic effects of angiotensin
16. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction
17. Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction
18. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: Evidence for the fibrinolytic system as an independent primary risk factor
19. Progression of coronary artery disease in young male post-infarction patients is linked to disturbances of carbohydrate and lipoprotein metabolism and to impaired fibrinolytic function
20. Daytime fluctuations in blood of tissue-type plasminogen activator (t-PA) and its fast-acting inhibitor (PAI-1)
21. Circadian variation of fibrinolytic activity in blood
22. Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1
23. Circadian variation in the frequency of onset of acute myocardial infarction
24. Prospective study of endogenous tissue plasminogen activator and risk of stroke
25. Predictive value of tissue plasminogen activator mass concentration on long-term mortality in patients with coronary artery disease: A 7-year follow-up
26. Clearance of tissue plasminogen activator (TPA) and TPA/plasminogen activator inhibitor type 1 (PAI-1) complex: Relationship to elevated TPA antigen in patients with high PAI-1 activity levels
27. Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction
28. Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)
29. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure
30. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: Results of the Survival and Ventricular Enlargement trial
31. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: The Heart Outcomes Prevention Evaluation Study Investigators
32. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions
33. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases
34. Implications of local angiotensin production in cardiovascular physiology and pharmacology
35. Molecular biology of the angiotensin I converting enzyme: II. Structure-function. Gene polymorphism and clinical implications
36. Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans
37. Role of endogenous bradykinin in human coronary vasomotor control
38. ACE inhibitors promote nitric oxide accumulation to modulate myocardial oxygen consumption
39. Concomitant enhancement of NO-mediated vasodilation and pro-fibrinolytic activity by ACE-inhibition in patients with coronary artery disease
40. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II: Evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function
41. Bradykinin stimulates tissue plasminogen activator release in human vasculature
42. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells
43. Plasminogen activator inhibitor-1 expression is regulated by the angiotensin type 1 receptor in vivo
44. Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 production
45. Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV
46. Selective stimulation of tissue-type plasminogen activator (t-PA) in vivo by infusion of bradykinin
47. Effect of early enalapril therapy on left ventricular function and structure in acute myocardial infarction
48. The early beneficial effect of treatment with oral ACE-inhibitors in patients with acute MI
49. Enalapril related changes in the fibrinolytic system in survivors of myocardial infarction
50. Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo
51. Endothelial control of the cardiovascular system: Recent advances
52. The role of nitric oxide in atherosclerosis
53. Chronic blockade of nitric oxide synthesis in the rat produces systemic hypertension and glomerular damage
54. Chronic inhibition of endothelium-derived nitric oxide synthesis causes coronary microvascular structural changes and hyperreactivity to serotonin in pigs
55. Chronic inhibition of nitric oxide synthesis causes coronary microvascular remodeling in rats
56. Important role of tissue angiotensin-converting enzyme activity in the pathogenesis of coronary vascular and myocardial structural changes induced by long-term blockade of nitric oxide synthesis in rats
57. Angiotensin-converting enzyme inhibitor prevents plasminogen activator inhibitor-1 expression in a rat model with cardiovascular remodeling induced by chronic inhibition of nitric oxide synthesis
58. Endothelial dysfunction: Clinical implications
59. Cardiac angiotensin II receptors are upregulated by long-term inhibition of nitric oxide synthesis in rats
60. Chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade: Effects on cardiovascular remodeling in rats induced by the long-term blockade of nitric oxide synthesis